Effects of beta-adrenergic blockade on survival of patients with chronic heart failure

American Journal of Cardiology

Volumn 80, Issue 11 A, 1997, Pages

  Packer, Milton ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISOPROLOL; CARVEDILOL; METOPROLOL;

BETA ADRENERGIC RECEPTOR BLOCKING; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; HEART FAILURE; HUMAN; PRIORITY JOURNAL; SURVIVAL RATE; SYMPATHETIC TONE; TREATMENT OUTCOME; VASODILATATION;

EID: 0030663133     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00848-5     Document Type: Conference Paper

References (39)

1. Packer M. The neurohormonal hypothesis a theory to explain the mechanism of disease progression in heart failure . J Am Coll Cardiol. 20:1992;248-254.
2. Bristow MR. Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents. Am J Cardiol. 71:1993;12C-22C.
3. Mulieri LA, Hasenfuss G, Leavitt B, Allen PD, Alpert NR. Altered myocardial force-frequency relation in human heart failure. Circulation. 85:1992;1743-1750.
4. Olivetti G, Abbi R, Quaini F, Kajstura J, Cheng W, Nitahara JA, Quaini E, Di Loreto C, Beltrami C, Krajewski S, Reed JC, Anversa P. Apoptosis in the failing human heart. N Engl J Med. 336:1997;1131-1141.
5. Sabbah HN, Shimoyama H, Kono T, Gupta RC, Sharov VG, Scicli G, Levine TB, Goldstein S. Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction. Circulation. 89:1994;2852-2859.
6. McDonald KM, Rector T, Carlyle PF, Francis GS, Cohn JN. Angiotensin-converting enzyme inhibition and beta-adrenoceptor blockade regress established ventricular remodeling in a canine model of discrete myocardial damage. J Am Coll Cardiol. 24:1994;1762-1768.
7. Donck L, Wouters L, Olbrich HG, Mutschler E, Borgers M. Nebivolol increases survival in cardiomyopathic hamsters with congestive heart failure. J Cardiovasc Pharmacol. 18:1991;1-3.
8. Guidelines for the evaluation and management of heart failure. J Am Coll Cardiol. 26:1995;1376-1398.
9. Chadda K, Goldstein S, Byington R, Curb JD. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation. 73:1986;503-510.
10. Anderson JL, Lutz JR, Gilbert EM, Sorensen SG, Yanowitz FG, Menlove RL, Bartholomew M. A randomized trial of low-dose beta-blockade therapy for idiopathic dilated cardiomyopathy. Am J Cardiol. 55:1985;471-475.
11. Krum H, Sackner-Bernstein JD, Goldsmith RL, Kukin ML, Schwartz B, Penn J, Medina N, Yushak M, Horn E, Katz SD, Levin HR, Neuberg GW, DeLong G, Packer M. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation. 92:1995;1499-1506.
12. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Johnson M, Silver MA, Gilbert EM, Hjalmarson Å. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 342:1993;1441-1446.
13. A randomized trial of β blockade in heart failure the Cardiac Insufficiency Bisoprolol Study (CIBIS) . Circulation. 90:1994;1765-1773.
14. Ruffolo RR Jr, Gellai M, Heible JP, Willette RN, Nicholas AJ. The pharmacology of carvedilol. Eur J Clin Pharmacol. 38:(suppl 2):1990;S82-S88.
15. Yue T-L, Ma X-L, Chen X-S, Louden C, Ruffolo RR, Feuerstein GZ. Carvedilol prevents cardiac ischemic damage and apoptosis in rabbit cardiomyocytes (Abstr.). Circulation. 94:(suppl I):1996;I-226.
16. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 334:1996;1349-1355.
17. Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, Sackner-Bernstein JD, Young ST, Holcslaw TL, Lukas MA. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation. 94:1996;2800-2806.
18. Packer M, Colucci WS, Sackner-Bernstein JD, Liang C-S, Goldscher DA, Freeman I, Kukin ML, Kinhal V, Udelson JE, Klapholz M, Gottlieb SS, Pearle D, Cody RJ, Gregory JJ, Kantrowitz NE, LeJemtel TH, Young ST, Lukas MA, Shusterman NH. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure The PRECISE Trial . Circulation. 94:1996;2793-2799.
19. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 94:1996;2807-2816.
20. Cohn JN, Fowler MB, Bristow MR, et al. Safety and efficacy of carvedilol in severe heart failure. J Card Failure. 3:1997;in press.
21. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet. 349:1997;375-380.
22. Bristow MR, Hershberger RE, Port JD, Gilbert EM, Sandoval A, Rasmussen R, Cates AE, Feldman AM. β-adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation. 82:(suppl II):1990;112-125.
23. 1-adrenergic receptors in the nonfailing and failing human heart. J Pharmacol Exp Ther. 247:1988;1039-1045.
24. Belch JJF, Budges AB, Scott N, Chopra M. Oxygen free radicals and congestive heart failure. Br Heart J. 65:1991;245-248.
25. Sole MJ, Schimmer J, Goldstein D, Li R-K. Oxidative stress contributes to decompensation of the failing heart. (Abstr.). Circulation. 92:(suppl I):1995;I-31.
26. 1 vs nonselective β-blockade in human congestive heart failure acute effects on cardiac sympathetic activity. (Abstr.) . Circulation. 92:(suppl I):1995;I-395.
27. 1A-adrenergic receptor subtype mediates biochemical, molecular, and morphologic features of cultured myocardial cell hypertrophy. J Biol Chem. 268:1993;15374-15380.
28. 1-adrenergic receptor subtype is responsible for delayed afterdepolarizations and triggered activity during simulated ischemia and reperfusion of isolated canine Purkinje fibers. Circulation. 84:1991;1732-1740.
29. Dhalla AK, Singh N, Singal PK. Antioxidant therapy associated with reversal of oxidative stress delays the pathogenesis of heart failure. (Abstr.). Circulation. 90:(suppl I):1994;I-491.
30. Lechat PP, Chalon S, Cucherat M, Packer M, Boissel JP. Meta-analysis of randomized clinical trials on beta-blocker treatment in heart failure. (Abstr.). Circulation. 94:(suppl I):1996;I-665.
31. Doughty RN, Rodgers A, Sharpe N, MacMahon S. Effects of beta-blocker therapy on mortality in patients with heart failure a systematic overview of randomized controlled trials . Eur Heart J. 18:1997;560-565.
32. Heidenreich PA, Lee TT, Massie BM. Effect of beta-blockade on mortality in patients with heart failure a meta-analysis of randomized clinical trials . J Am Coll Cardiol. 30:1997;27-34.
33. 2-adrenergic stimulation in animals susceptible for sudden death . Circulation. 96:1997;1914-1922.
34. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA. 273:1995;1450-1456.
35. Pfeffer MA, Stevenson LW. β-adrenergic blockers and survival in heart failure. N Engl J Med. 334:1996;1396-1397.
36. Moye LA, Abernethy D. Carvedilol in patients with chronic heart failure (Letter.). N Engl J Med. 335:1996;1318.
37. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 325:1991;293-302.
38. Feldman AM, Bristow MR, Parmley WW, Carson PE, Pepine CJ, Gilbert EM, Strobeck JE, Hendrix GH, Powers ER, Bain RP. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med. 329:1993;149-155.
39. Bristow MR, O'Connell JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, Orie J, Smucker ML, Marshall G, Kelly P. Dose response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation. 84:1994;1632-1642.